Moreover, J-ALEX study indicated that alectinib (second-generation ALK inhibitors) reduced the risk of disease worsening or death by 66 percent compared to crizotinib ((HR = 0.34, 99 percent CI: 0.17–0.70, p < 0.0001) and had the potential to become first-line therapy in patients with ALK-positive NSCLC [40]. Here, ALK is linked to non-small cell lung carcinoma.